Similarly, research by Menyhárt et al. revealed that EPB41L2, one of four genes (alongside HLA-DQB1, LTF, and SFRP1), is consistently overexpressed in tumor samples from ovarian cancer patients with disease progression after topotecan therapy (39). This evidence concerns the gene SFRP1 and ovarian carcinoma.